Jump to main content
Jump to site search

Issue 23, 2016
Previous Article Next Article

Lectin-based lateral flow assay: proof-of-concept

Author affiliations


Lateral flow assays (LFAs) enable the simple and rapid detection and quantification of analytes and is popular for point-of-care (PoC), point-of-use and outdoor testing applications. LFAs typically depend on antibody or nucleic acid based recognition. We present the innovative concept of a LFA using lectins in the role of the biorecognition element. Lectins are a special kind of glycan-binding protein and the lectin-based LFA herein described was developed for the determination of the glycosylation of free prostate specific antigen (PSA). PSA is routinely used as a biomarker of prostate cancer (PCa) and the glycosylation status of PSA is a more specific marker of disease progress than only the PSA level. Using the lectin-based LFA we were able to detect α-2,6 sialic acid present in fPSA using Sambucus nigra (SNA) lectin. As a negative control, we employed Maackia amurensis lectin II (MAA II) which specifically binds α-2,3 sialic acid. The novel approach presented here can be applied to a wide range of biomarkers that have a significant impact on clinical diagnosis and prognosis, providing an alternative to standard lectin-based assays. The assay uses commercial components and is easily performed by applying a sample to the sampling pad on the lectin-based LFA strip, with results obtained within 10 minutes.

Graphical abstract: Lectin-based lateral flow assay: proof-of-concept

Back to tab navigation

Publication details

The article was received on 02 Aug 2016, accepted on 07 Oct 2016 and first published on 07 Oct 2016

Article type: Paper
DOI: 10.1039/C6AN01746K
Citation: Analyst, 2016,141, 6444-6448

  •   Request permissions

    Lectin-based lateral flow assay: proof-of-concept

    P. Damborský, K. M. Koczula, A. Gallotta and J. Katrlík, Analyst, 2016, 141, 6444
    DOI: 10.1039/C6AN01746K

Search articles by author